Cardiovascular Risk Factors Clinical Trials

12 recruiting

Cardiovascular Risk Factors Trials at a Glance

15 actively recruiting trials for cardiovascular risk factors are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in Adelaide, Aix-en-Provence, and Amsterdam. Lead sponsors running cardiovascular risk factors studies include Consorzio Mario Negri Sud, Fundación Universitaria del Area Andina, and Charite University, Berlin, Germany.

Browse cardiovascular risk factors trials by phase

Treatments under study

About Cardiovascular Risk Factors Clinical Trials

Looking for clinical trials for Cardiovascular Risk Factors? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cardiovascular Risk Factors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cardiovascular Risk Factors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Not Applicable

Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

Heart FailureCardiovascular Risk Factors
Idoven 1903 S.L.1,968 enrolled5 locationsNCT07113223
Recruiting
Not Applicable

Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study

ObesityHypertensionOverweight+4 more
Universidad Católica San Antonio de Murcia220 enrolled1 locationNCT07447362
Recruiting
Not Applicable

Sleep and Circadian Mechanisms in Hypertension

Cardiovascular DiseasesHypertensionSleep+2 more
Oregon Health and Science University32 enrolled1 locationNCT05184933
Recruiting
Not Applicable

Velocity-Based Resistance Training in Kidney Transplant Recipients

Metabolic SyndromeCardiovascular Risk FactorsKidney Transplant Recipients
Fundación Universitaria del Area Andina12 enrolled1 locationNCT07370727
Recruiting
Not Applicable

The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.

Cardiovascular DiseasesCholesterolDyslipidemia+2 more
University of Toronto1,100 enrolled1 locationNCT06919302
Recruiting

Redirecting Poor Sleep Drivers of Early Cardiovascular Disease

SleepCardiovascular Risk Factors
National University of Singapore1,500 enrolled1 locationNCT06949722
Recruiting

Types of Intracellular Bacteria in Atherosclerotic Plaques and Analysis of Risk Factors

DiabetesCarotid Artery StenosisHyperlipidemia+6 more
Tang-Du Hospital200 enrolled1 locationNCT06935279
Recruiting

The Oxford Risk Factors And Non-Invasive Imaging Study

Cardiovascular DiseasesCardiovascular Risk Factors
University of Oxford250,000 enrolled37 locationsNCT05169333
Recruiting
Not Applicable

Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population

Cardiovascular Risk FactorsAdherence, MedicationPrimary Prevention+1 more
Zhang longjiang,MD3,400 enrolled1 locationNCT05725096
Recruiting
Not Applicable

Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors

Coronary Heart DiseasePhysical ActivityCardiovascular Risk Factors
University Hospital, Basel, Switzerland100 enrolled1 locationNCT05969665
Recruiting

Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach

Immune SystemGut MicrobiomeTransgender+1 more
Charite University, Berlin, Germany200 enrolled1 locationNCT05334888
Recruiting

Swiss Longitudinal Cohort

Cardiovascular Risk Factors
Hypertension Excellence Centre Lucerne1,000 enrolled3 locationsNCT02282748
Recruiting

Integrated Care for Atrial Fibrillation Management: A Randomised Controlled Trial

Atrial FibrillationCardiovascular Risk Factors
Royal Adelaide Hospital1,376 enrolled6 locationsACTRN12616001109493
Recruiting
Phase 3

A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV)

To assess the benefit/risk profile of cytoreductive therapy with phlebotomy and/or hydroxyurea (HU) aimed at maintaining hematocrit (HCT) < 45% Vs. maintaining HCT in the range of 45-50% in patients with PV treated at the best of recommended therapies (e.g., low dose of aspirin when indicated and adequated control of standard cardiovascular risk factors)
Consorzio Mario Negri Sud1,000 enrolled1 locationACTRN12609000046202
Recruiting
Phase 3

Long term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.

Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
Consorzio Mario Negri Sud2,100 enrolled1 locationACTRN12607000333415